Early stage (I, II, III) melanoma

Current Treatment Options in Oncology

Volumn 2, Issue 3, 2001, Pages 183-191

  Sondak, Vernon K ^a   Ross, Merrick I ^a   Schuchter, Lynn M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Lymphedema; Melanoma; Melanoma Patient; Sentinel Node; Sentinel Node Biopsy

Indexed keywords

BIOPSY; CANCER STAGING; HUMAN; LYMPH NODE; LYMPHADENECTOMY; MELANOMA; PATHOLOGY; REVIEW; SKIN TUMOR;

BIOPSY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 0035382939     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0032-6     Document Type: Article

References (41)

1. Karakousis CP, Balch CM, Urist MM, et al.:Local recurrence in malignant melanoma: long-term results of the multi-institutional randomized surgical trial. Ann Surg Oncol 1996, 3:446. DOI: 10.1007/BF02305762
2. Veronesi U, Cascinelli N: Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991, 126:438–441.
3. Ringborg U, Anderrsson R, Eldh J, et al.: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996, 77:1809–1814. DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1809::AID-CNCR8>3.0.CO;2-6
4. Balch CM, Urist MM, Karakousis CP, et al.: Efficacy of 2-cm surgical margins for intermediate thickness melanomas (1 to 4 mm). Ann Surg 1993, 218:262. DOI: 10.1097/00000658-199309000-00005
5. Heaton KM, Sussman JJ, Gershenwald JE, et al.: Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 1998, 5:322–328. DOI: 10.1007/BF02303495
6. Zitelli JA, Brown CD, Hanusa BH: Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol 1997, 37:422–429. DOI: 10.1016/S0190-9622(97)70144-0
7. Morton D, Wen D, Wong J, et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392–299.
8. Reintgen D, Cruse C, Wells K, et al.: The orderly progression of melanoma nodal metastases. Ann Surg 1994, 220:759–767. DOI: 10.1097/00000658-199412000-00009
9. Thompson J, McCarthy W, Bosch C, et al.: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995, 5:255–260.
10. Gershenwald JE, Tseng CH, Thompson W, et al.:Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 1998, 124:203–210.
11. Gershenwald JE, Colome MI, Lee JE, et al.: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998, 16:2253–2260.
12. Balch CM, Soong S, Ross MI, et al.: Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000, 7:87–97. DOI: 10.1007/s10434-000-0087-9
13. Cascinelli N, Morabito A, Santinami M, et al.:Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998, 351:793–796. DOI: 10.1016/S0140-6736(97)08260-3
14. Gershenwald JE, Thompson W, Mansfield PF, et al.:Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976–983.
15. Morton DL, Thompson JF, Essner R, et al.: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early stage melanoma. Ann Surg 1999, 230:453–465. Important clinical trial establishing the utility of lymph node mapping. DOI: 10.1097/00000658-199910000-00001
16. Clary BM, Brady MS, Lewis JJ, Coit DG: Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001, 233:250–258. DOI: 10.1097/00000658-200102000-00015
17. Gershenwald JE, Mansfield PF, Lee JE, Ross MI: Role for lymphatic mapping and sentinel lymph node biopsy in patient with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000, 7:160–165. DOI: 10.1007/s10434-000-0160-4
18. Balch CM, Ross MI: Melanoma patients with iliac nodal metastases can be cured. An editorial. Ann Surg Oncol 1999, 6:230–231. DOI: 10.1007/s10434-999-0230-1
19. Coit DG, Brennan MF: Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989, 124:162–166.
20. Beitsch P, Balch C: Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection. Am J Surg 1992, 164:462–465. DOI: 10.1016/S0002-9610(05)81181-X
21. Kirkwood JM, Ibrahim JG, Sondak VK, et al.: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18:2444–2454. This controversial trial confirmed the relapse-free survival improvement associated with high-dose interferon but showed no evidence of a survival advantage. Crossover of patients from the control arm upon regional relapse may have limited the ability of this study to detect a survival difference.
22. Livingston PO, Wong GYC, Adluri S, et al.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994, 12:1036–1044.
23. Kirkwood JM, Sosman JA, Ernstoff MS, et al.: Overview of the role of high-dose IFNa2b (HDI) in the therapy of high-risk resectable melanoma [abstract]. J Immunother 2000, 23:595.
24. Cascinelli N, Bufalino R, Morabito A, MacKie RM:Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994, 343:913–914. DOI: 10.1016/S0140-6736(94)90030-2
25. Rusciani L, Petraglia S, Alotto M, et al.: Postsurgical adjuvant therapy of melanoma: evaluation of a 3-year randomized trial with recombinant interferon-a after 3 and 5 years of follow-up. Cancer 1997, 79:2354–2360. DOI: 10.1002/(SICI)1097-0142(19970615)79:12<2354::AID-CNCR9>3.0.CO;2-L
26. Pehamberger H, Soyer HP, Steiner A, et al.: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998, 16:1425–1429.
27. Grob JJ, Dreno B, de la Salmoniere P, et al.: Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998, 351:1905–1910. DOI: 10.1016/S0140-6736(97)12445-X
28. Islam M, Frye R, Richards T, et al.: Differential effect of IFN a-2b on CYP450 enzyme system: a potential issue of IFN toxicity and its modulation [sic] by other drugs [abstract]. Proc Am Soc Clin Oncol 1999, 18:539a.
29. Trask PC, Esper P, Riba M, Redman B: Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000, 18:2316–2326. A comprehensive review of the psychiatric adverse reactions associated with interferon therapy. A must for the medical oncologist who administers high-dose interferon.
30. Jonasch E, Kumar UN, Linette GP, et al.: Adjuvant highdose interferon alfa-2b in patients with high-risk melanoma. Cancer J Sci Am 2000, 6:139–145.
31. Hillner BE, Kirkwood JM, Atkins MB, et al.: Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1998, 15:2351–2358.
32. Ang KK, Peters LJ, Weber RS, et al.: Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994, 30:795–798.
33. Strom EA, Ross MI: Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995, 2:445–449. DOI: 10.1007/BF02306379
34. O’Brien CJ, Petersen-Schaefer K, Stevens GN, et al.:Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997, 19:589–594. DOI: 10.1002/(SICI)1097-0347(199710)19:7<589::AID-HED5>3.0.CO;2-3
35. Creagan ET, Cupps RE, Ivins JC, et al.: Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer 1978, 42:2206–2210. DOI: 10.1002/1097-0142(197811)42:5<2206::AID-CNCR2820420518>3.0.CO;2-S
36. Shen P, Wanek LA, Morton DL: Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanoma? Ann Surg Oncol 2000, 7:554–559. DOI: 10.1007/s10434-000-0114-x
37. Thompson LW, Brinckerhoff L, Slingluff CL: Vaccination for melanoma. Curr Oncol Rep 2000, 2:292–299. An excellent review of the current status of vaccine therapy for melanoma. DOI: 10.1007/s11912-000-0021-0
38. Hersey P: Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann N Y Acad Sci 1993, 690:167–177. DOI: 10.1111/j.1749-6632.1993.tb44006.x
39. Wallack MK, Sivanandham M, Balch CM, et al.: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998, 187:69–79. DOI: 10.1016/S1072-7515(98)00097-0
40. Haigh PI, DiFronzo LA, Gammon G, Morton DL:Vaccine therapy for patients with melanoma. Oncology 2000, 13:1561–1574.
41. Sondak VK, Liu P-Y, Tuthill RJ, et al.: SWOG-9035: Adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine [abstract]. J Immunother 2000, 23:600.